<DOC>
	<DOCNO>NCT02601248</DOCNO>
	<brief_summary>First-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , safety tolerability , pharmacokinetics ( PK ) , preliminary anti-tumor activity Theliatinib .</brief_summary>
	<brief_title>Study Theliatinib ( HMPL-309 ) Patients With Advanced Solid Tumor</brief_title>
	<detailed_description>Theliatinib ( HMPL-309 ) new constructive , high effective , high selective , EGFR tyrosine kinase inhibitor . Theliatinib demonstrate strong inhibitory effect multiple tumor overexpressed EGFR sensitive EGFR mutation . This first-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , safety tolerability , pharmacokinetics ( PK ) , preliminary anti-tumor activity Theliatinib .</detailed_description>
	<criteria>Histopathology confirm solid tumor Failed standard treatment standard treatment uncontrolled , recurrent and/or metastatic advance tumor ( whatever previous surgery condition ) Age 1875 Performance status 0 , 1 , bad within 7days Life expect &gt; 3 month Written inform consent form voluntarily Lab test within 1 week enrol , AND &lt; 1.5×109/L , platelet &lt; 75×109/L , Hb &lt; 9g/dL , Total bilirubin≥1.5× upper limit normal , Serum creatinine high normal range Diastolic pressure≥150mmHg systolic pressure≥100mmHg whatever antihypertension drug use , Serum potassium ( whenever potassium implement ) , serum calcium ( ionic albumintype calcium ) serum magnesium outside normal range ( whenever implement ) Within previous 4 week treat systemic antitumor therapy , radiotherapy , immune therapy , biological hormonal therapy , clinical trial . But exclude therapy , Prostate cancer treat hormonal therapy GnRH analogue antagonist Hormone replacement therapy oral contraceptive Palliative radiotherapy bone metastasis within 2 week Prior documental evidence resistance ( epidermal growth factor receptortyrosine kinase inhibitor ) Unrecovered previous therapy relate toxicity to≤ CTCAE ( Common Toxicity Criteria Adverse Effects ) 0 1or unrecovered previous surgery Any CNS ( central nervous system ) metastasis uncontrolled symptom Known dysphagia drug malabsorption Active infection acute pneumonia , hepatitis B active period APTT ( activate partial thromboplastin time ) and/or INR ( international normalize ratio ) , PT≥2 ULN ( upper limit normal ) ( include patient treated anticoagulation treatment ) ocular surface diseases dry eye syndrome skin disease obvious symptom sign significant cardiovascular disease , include IIIV atrioventricular block , acute myocardial infarction within 6 month , significant angina Coronary artery bypass graft Known exist interstitial lung disease Female patient pregnant feeding , childbearing potential patient pregnant test positive Any abnormal clinical laboratory patient unsuitable attend trial sine opinion investigator Patients unable comply protocol since significant psychological psychogenic abnormal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>safety , PK</keyword>
</DOC>